Skip to main content

Table 3 Incidence of adverse events

From: Safety, tolerability, clinical, and joint structural outcomes of a single intra-articular injection of allogeneic mesenchymal precursor cells in patients following anterior cruciate ligament reconstruction: a controlled double-blind randomised trial

 

MPC + HA (n = 11)

HA alone (n = 6)

Total number of adverse events

94

39

 Non-serious, n (%)

92 (97.9)

39 (100.0)

 Serious, n (%)

2 (2.1)#

0 (0.0)

Adverse events by system organ class*, n (grade)

 Musculoskeletal and connective tissue disorders

11 (2)

6 (1)

 General disorders and administration site conditions

3 (2)

1 (1)

 Injury, poisoning, and procedural complications

2 (1)

2 (1)

 Infections and infestations

1 (1)

1 (1)

 Respiratory, thoracic, and mediastinal disorders

1 (1)

0

 Immune system disorders

2 (2)

1 (2)

  1. * Graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCICTCAE)
  2. # Non-treatment related